Insider Trading
| VIRXDelisted Stock | USD 0.03 0 7.38% |
Slightly above 62% of Viracta Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Viracta Therapeutics pink sheet suggests that many investors are alarmed at this time. Viracta Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Viracta Therapeutics' earnings reports, geopolitical events, and overall market trends.
Viracta |
Filed transaction by Viracta Therapeutics Executive. Insider Public Trading
Read at macroaxis.com
Viracta Therapeutics Fundamental Analysis
We analyze Viracta Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viracta Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viracta Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Viracta Therapeutics is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Viracta Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Viracta Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of Viracta Therapeutics could also be used in its relative valuation, which is a method of valuing Viracta Therapeutics by comparing valuation metrics with similar companies.
Peers
Viracta Therapeutics Related Equities
| LPTX | Leap Therapeutics | 16.28 | ||||
| XFOR | X4 Pharmaceuticals | 3.85 | ||||
| VINC | Vincerx Pharma | 3.45 | ||||
| MREO | Mereo BioPharma | 0.85 | ||||
| TNYA | Tenaya Therapeutics | 1.32 | ||||
| BCYC | Bicycle Therapeutics | 1.36 | ||||
| TRVI | Trevi Therapeutics | 2.12 | ||||
| IGMS | IGM Biosciences | 2.38 | ||||
| EYPT | Eyepoint Pharmaceuticals | 2.88 | ||||
| GLUE | Monte Rosa | 3.17 | ||||
| RLYB | Rallybio Corp | 3.42 | ||||
| TARA | Protara Therapeutics | 4.23 | ||||
| STOK | Stoke Therapeutics | 4.39 | ||||
| INZY | Inozyme Pharma | 4.95 | ||||
| CABA | Cabaletta Bio | 5.42 | ||||
| ALXO | Alx Oncology | 5.61 | ||||
| TERN | Terns Pharmaceuticals | 6.63 | ||||
| BMEA | Biomea Fusion | 9.68 | ||||
| LYRA | Lyra Therapeutics | 11.11 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Viracta Pink Sheet
If you are still planning to invest in Viracta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viracta Therapeutics' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Commodity Directory Find actively traded commodities issued by global exchanges |